

**中国医药外包年鉴 2009**



**China Pharma Outsourcing  
Annual Review 2009**

**By Jim J. Zhang, Ph.D.**

**November, 2009**

# Table of Contents

<b>Scope of the Report</b> .....	<b>2</b>
<b>About the Author</b> .....	<b>3</b>
<b>Executive Summary</b> .....	<b>11</b>
Review of Market Development in 2009 .....	12
▪ Review on what happened to the global pharma and biotech industries in 2009 .....	12
▪ Review on what happened to the Chinese pharma outsourcing industry in 2009 .....	13
▪ Review on market development of Chinese pharma outsourcing industry in 2009 .....	14
▪ Review on 2009 growth drivers of the Chinese pharma outsourcing industry .....	14
Review of Major Events and Industry Developments in 2009 .....	15
▪ Review on major activities in 2009 .....	15
▪ Chinese service providers strengthening their service capability .....	16
▪ Review on major events in 2009 .....	16
Current Top Ten Players .....	17
Outlook of 2010 .....	19
▪ How global pharma and biotech industries will move in 2010 .....	19
▪ Strategies major pharma companies will take in 2010 .....	20
▪ How global pharma outsourcing will be affected in 2010 .....	20
▪ New strategies major pharma will likely implement in selecting their service providers .....	21
▪ Outlook of Chinese pharma outsourcing industry in 2010 .....	21
▪ How each service sector of Chinese pharma outsourcing industry will move in 2010 .....	22
▪ New development trends in the Chinese pharma outsourcing industry in 2010 .....	23
<b>Chapter 1. Review of Market Development in 2009</b> .....	<b>24</b>
Summary .....	25
1.1 Introduction .....	28
1.2 What happened to the global pharmaceutical and biotech industries in 2009? – Analysis of the impacts of the financial crisis on both pharma and biotech industries .....	29
1.3 What happened to the global pharma outsourcing industry in 2009?	

– Analysis of the impacts of the financial crisis on the global pharma outsourcing industry -----	32
1.4 How did Chinese pharma outsourcing industry weather the crisis?	
– Analysis of the impacts of the financial crisis on the Chinese pharma outsourcing industry -----	36
1.4.1 What did JZMed predict at the beginning of 2009? -----	37
1.4.2 How did the Chinese pharma outsourcing industry actually move in 2009? -----	39
1.5 How was each service sector affected by the financial crisis?	
– Analysis of the impacts of the financial crisis on each service sector of the Chinese pharma outsourcing industry and their current market sizes -----	42
1.5.1 Early stage drug discovery service -----	42
a. Analysis of the impacts of the financial crisis on early stage drug discovery service -----	42
b. Current market size of early stage drug discovery service -----	43
1.5.2 Preclinical research service -----	44
a. Analysis of the impacts of the financial crisis on preclinical research service -----	44
b. Current market size of preclinical research service -----	44
1.5.3 Clinical research service -----	45
a. Analysis of the impacts of the financial crisis on clinical research service -----	45
b. Current market size of clinical research service -----	45
1.5.4 Contract manufacturing service -----	45
a. Analysis of the impacts of the financial crisis and other factors on contract manufacturing service -----	45
b. Current market size of contract manufacturing service -----	47
1.6 An overview of the current state of the Chinese pharma outsourcing industry ---	49
1.6.1 Three development stages in the short history of the Chinese pharma outsourcing industry -----	49
1.6.2 Current overall state of the Chinese pharma outsourcing industry -----	49
1.6.3 Current total market size of the Chinese pharma outsourcing industry --	51
1.6.4 Current service capability of the Chinese pharma outsourcing industry -	53
a. Current service capability in early stage drug discovery -----	53
b. Current service capability in preclinical research -----	55
c. Current service capability in late stage development -----	57
d. Current service capability in contract manufacturing -----	58
1.6.5 Geographic distributions of Chinese service providers -----	60
<b>Chapter 2. Review of Major Events and Industry Developments in 2009 -----</b>	<b>62</b>
Summary -----	63
2.1 Introduction -----	65
2.2 Major pharma companies continue spending and expanding their operations in China -----	67
a. Bayer Schering will invest \$129 M to establish an R&D center	

in China -----	68
b. Novartis expects its China sales revenue to grow by 45% in 2009 and invests \$1.25 B to build its third global R&D center in China -----	69
c. Eli Lilly announced to double its employee size and expand its operation in China -----	70
d. GSK targets China's vaccine market -----	71
e. Merck AG to train Chinese pharmacists -----	71
f. Novozymes plans to manufacture hyaluronic acid (bHA) in China -----	72
g. Sanofi-Aventis is going to relocate and further expand its China manufacturing facilities in Hangzhou -----	72
h. Pfizer announced research collaborations with two Chinese institutions -----	73
i. Boehringer Ingelheim to further expand its China operation -----	74
2.3 Foreign biotech companies set up their R&D divisions in China -----	74
a. FORMA Therapeutics established an R&D center in Beijing -----	74
b. AlphaRx opened an R&D center in China -----	74
2.4 What happened to the CMO sector of the Chinese pharma outsourcing industry in 2009?	
– Analysis of the development of contract manufacturing service in China in 2009 -----	75
2.5 State Council issued special guidelines to encourage local government to improve environment for outsourcing service -----	78
2.6 Increasing numbers of multinational pharma outsourcing service providers have entered the Chinese market -----	79
2.6.1 Foreign CROs opened subsidiaries/divisions in China -----	80
a. e-Therapeutics set up a new site in Nanjing to offer computational services -----	80
b. SGS opened new micro test lab in China -----	81
c. Sparta brought pharma quality management service to Asia -----	81
d. XBL opened its China lab -----	81
e. LGC opened its China office to raise local lab standards -----	82
2.6.2 Foreign CROs formed JVs or partnerships with Chinese counterparts --	82
a. Cogenics partnered with SinoGenoMax to offer genomic services in China -----	82
b. GVK formed partnership with Excel PharmaStudies -----	82
c. Clinilabs formed partnership with H&J -----	82
2.6.3 Foreign CROs acquired Chinese counterparts to enter the Chinese market -----	83
a. ReSearch bought Chinese CRO Paramax International -----	83
b. CBI acquired Shanghai-based GL Biochem to enter the booming peptide outsourcing market in China -----	83
c. PerkinElmer acquired Chinese diagnostic company to enter the Chinese market -----	83
d. PPD to acquire Exel PharmaStudies to strengthen its position	

in China -----	84
2.7 China-based CROs formed partnerships/alliances to strengthen their service capability -----	84
a. Two Shanghai-based Chinese CROs formed alliance -----	74
b. ChemWerth formed partnership with Tianjin Tianyao Pharmaceuticals Co. -----	84
c. Twenty CROs in Guangzhou formed an alliance -----	85
2.8 Major outsourcing deals struck in 2009 between foreign pharma/biotech companies and China-based service providers -----	85
a. BioDuro struck contracts with AstraZeneca and Roche on drug discovery research -----	85
b. HD Biosciences secured contract with CellCentric for compound screening and other drug discovery work -----	86
c. ChemPartner successfully secured a series of contracts -----	86
2.9 Chinese CROs expanded service capability -----	87
a. Asymchem Laboratories opened a high potency API manufacturing facility in Tianjin -----	87
b. Sundia MediTech acquired protein folding technology -----	87
2.10 Venture capitals invested in Chinese CROs -----	87
a. A \$15 M investment made by Kleiner Perkins into Chinese CRO Jinsite -----	88

**Chapter 3. Current Top Ten Players ----- 89**

Summary -----	90
3.1 Introduction -----	93
3.2 Evaluation of China-based pharma outsourcing service providers -----	94
3.3 Classification of players -----	94
3.4 Classification and definition of service capability -----	96
3.5 Selection of top ten players of Chinese pharma outsourcing industry -----	98
3.6 Description of top ten players -----	101

**Chapter 4. Outlook of 2010 ----- 129**

Summary -----	130
4.1 Introduction -----	134
4.2 Global pharma and biotech industries have been significantly altered by the financial crisis -----	134
4.2.1 A totally different biotech industry after the financial crisis -----	135
4.2.2 Major pharma companies have become stronger than ever -----	135
4.3 How will the global pharma outsourcing be affected? -----	136
4.3.1 Challenges facing global pharma and biotech companies -----	136
4.3.2 New operation strategies pharma/biotech industry will likely implement in 2010 and near future -----	138
4.3.3 How will the global pharma outsourcing industry be likely affected? --	138
1. Outsourcing demands by major pharma companies will likely	

still remain strong in following areas -----	140
2. Outsourcing demands by major pharma will likely become weak in the following areas -----	141
3. New strategies major pharma will likely implement in selecting their service providers -----	141
4. Outsourcing demands by small biotech companies will likely remain strong in the following areas -----	142
5. Outsourcing demands by small biotech companies will become weak in the following areas -----	142
6. Summary of the changes in outsourcing demands in 2010 by both pharma and biotech industries -----	142
4.3.4 What types of CROs/CMOs will become preferred service providers? -----	143
4.4 How will pharma outsourcing develop in China in 2010? -----	144
4.5 How will each service sector of Chinese pharma outsourcing industry move in 2010? -----	146
4.5.1 Early stage drug discovery -----	146
4.5.2 Preclinical development -----	148
4.5.3 Clinical research -----	149
4.5.4 Contract manufacturing -----	149
4.5.5 Summary of the growth forecasts of the Chinese pharma outsourcing industry in 2010 -----	150
4.6 New development trends in the Chinese pharma outsourcing industry in 2010 --	153
4.6.1 More consolidations -----	153
4.6.2 Chinese pharma outsourcing industry will gradually become mature with more, one-stop service providers to emerge -----	154
4.6.3 Licensing of generic drugs by major pharma companies -----	154
4.7 Key issues still facing all China-based pharma outsourcing service providers in 2010 -----	155
4.7.1 Fast rising of labor cost -----	155
4.7.2 Abiding by the international rule of the game -----	156
4.7.3 Competition from neighboring developing countries -----	156
4.7.4 Competition from Indian pharma outsourcing companies -----	156
1. Strengths and weakness of each country in pharma outsourcing -	157
2. Current market sizes of each country -----	158
4.8 How to effectively conduct outsourcing in China -----	158
4.8.1 Advices to companies sourcing APIs and raw materials in China -----	158
4.8.2 Advices to small biotech companies outsourcing in China -----	159
4.9 Key benefits of outsourcing to China -----	160
<b>About JZMed, Inc. -----</b>	<b>162</b>

## List of Tables

Table 1. Number of companies having announced restructure during the financial crisis -----	30
--	----

Table 2. Ortho-McNeil Jassen Pharmaceuticals outsourced early stage drug R&D projects to both Chinese and Indian companies simultaneously -----	34
Table 3. More examples of outsourcing collaborations happened recently between major Western pharma companies and Chinese companies/research organizations -----	34
Table 4. Market development of each service sector of Chinese pharma outsourcing industry in 2009 -----	48
Table 5. Comparison of market values in 2009 between China's CRO sector and its CMO sector -----	52
Table 6. Summary of major events and activities happened to the Chinese pharma outsourcing industry in 2009 -----	65
Table 7. Classification and definition of service capability of contract research organization-----	97
Table 8. Current top ten pharma outsourcing service providers in China -----	99
Table 9. Brief summary of WuXi PharmaTech -----	102
Table 10. Development history of WuXi PharmaTech (revenue and staff size) -----	102
Table 11. Company profile of WuXi PharmaTech -----	104
Table 12. Brief summary of ChemPartner -----	106
Table 13. Company profile of ChemPartner -----	107
Table 14. Brief summary of Asymchem Lab -----	109
Table 15. Company profile of Asymchem Lab -----	109
Table 16. Brief summary of BioDuro -----	111
Table 17. Company profile of BioDuro -----	112
Table 18. Brief summary of Venturepharm Lab -----	114
Table 19. Company profile of Venturepharm Lab -----	115
Table 20. Brief summary of Pharmaron -----	116
Table 21. Company profile of Pharmaron -----	117
Table 22. Brief summary of Medicilon -----	119
Table 23. Company profile of Medicilon -----	119
Table 24. Brief summary of Sundia Meditech -----	122
Table 25. Company profile of Sundia Meditech -----	122
Table 26. Brief summary of ShanghaiBio -----	124
Table 27. Company profile of ShanghaiBio -----	125
Table 28. Brief summary of Excel PharmaStudies -----	126
Table 29. Company profile of Excel PharmaStudies -----	127
Table 30. Summary of forecasted development trends of global pharma outsourcing industry in 2010 and beyond -----	143
Table 31. 2010 Market development forecast of Chinese pharma outsourcing industry -----	151
Table 32. 2010 Market development forecast of each service sector of the Chinese pharma outsourcing industry -----	151
Table 33. Growth forecast of China's CRO and CMO market in 2010 -----	152

## List of Figures

Figure 1. Graphic display of the number of companies having announced restructure

during the financial crisis -----	30
Figure 2. Predicted impacts of the financial crisis on Chinese pharma outsourcing industry -----	38
Figure 3. Quarter-over-quarter earning development trend of Chinese pharma outsourcing market during the financial crisis -----	41
Figure 4. Market value of each service sector in 2009 -----	48
Figure 5. An overview of the current situation of the Chinese pharma outsourcing industry -----	50
Figure 6. Chinese pharma outsourcing market: Development history and current size -----	52
Figure 7. Comparison of China's CRO and CMO market values in 2009 -----	52
Figure 8. Number of service providers in each service sector of the Chinese pharma outsourcing industry -----	60
Figure 9. Classification and rating of China-based CROs and CMOs -----	95
Figure 10. Estimated 2009 service revenues of top ten China-based pharma outsourcing service providers -----	100
Figure 11. WuXi PharmaTech's staff growth history and forecast -----	103
Figure 12. WuXi PharmaTech's revenue growth history and forecast -----	103
Figure 13. Strategies likely to be implemented by both major pharma and small biotech companies in 2010 and the near future -----	139
Figure 14. Forecasted market value of each service sector of the Chinese pharma outsourcing industry in 2010 -----	152
Figure 15. Forecasted China's CRO and CMO market values in 2010 -----	152